State Key Laboratory of Crystal Materials, Shandong University, Jinan, 250100, China.
Shandong BIOBASE Biology Co., Ltd, Jinan, 250000, Shandong, China.
Sci Rep. 2024 May 9;14(1):10646. doi: 10.1038/s41598-024-59525-2.
Individual theranostic agents with dual-mode MRI responses and therapeutic efficacy have attracted extensive interest due to the real-time monitor and high effective treatment, which endow the providential treatment and avoid the repeated medication with side effects. However, it is difficult to achieve the integrated strategy of MRI and therapeutic drug due to complicated synthesis route, low efficiency and potential biosafety issues. In this study, novel self-assembled ultrasmall FeO nanoclusters were developed for tumor-targeted dual-mode T/T-weighted magnetic resonance imaging (MRI) guided synergetic chemodynamic therapy (CDT) and chemotherapy. The self-assembled ultrasmall FeO nanoclusters synthesized by facilely modifying ultrasmall FeO nanoparticles with 2,3-dimercaptosuccinic acid (DMSA) molecule possess long-term stability and mass production ability. The proposed ultrasmall FeO nanoclusters shows excellent dual-mode T and T MRI capacities as well as favorable CDT ability due to the appropriate size effect and the abundant Fe ion on the surface of ultrasmall FeO nanoclusters. After conjugation with the tumor targeting ligand Arg-Gly-Asp (RGD) and chemotherapy drug doxorubicin (Dox), the functionalized FeO nanoclusters achieve enhanced tumor accumulation and retention effects and synergetic CDT and chemotherapy function, which serve as a powerful integrated theranostic platform for cancer treatment.
新型自组装超小 FeO 纳米团簇用于肿瘤靶向双模式 T/T2 加权磁共振成像(MRI)引导协同化学动力学治疗(CDT)和化学疗法。通过简单地用 2,3-二巯基丁二酸(DMSA)分子修饰超小 FeO 纳米颗粒合成的自组装超小 FeO 纳米团簇具有长期稳定性和大规模生产能力。由于合适的尺寸效应和表面上丰富的 Fe 离子,所提出的超小 FeO 纳米团簇表现出优异的双模式 T1 和 T2 MRI 能力以及良好的 CDT 能力。与肿瘤靶向配体 Arg-Gly-Asp(RGD)和化疗药物阿霉素(Dox)缀合后,功能化的 FeO 纳米团簇实现了增强的肿瘤积累和保留效果以及协同的 CDT 和化学疗法功能,可作为癌症治疗的强大集成治疗平台。
ACS Appl Mater Interfaces. 2020-5-20
Front Chem. 2025-5-26
Front Bioeng Biotechnol. 2025-5-12
Front Bioeng Biotechnol. 2024-11-19
ACS Appl Mater Interfaces. 2022-7-6
Nat Mater. 2020-1-13
J Am Chem Soc. 2019-9-30